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ously bind to EGFR domain III, the bind-
ing of Matuzumab would interfere with 
formation of the active-like EGFR confor-
mation (Figure 1A, middle panel). Thus, in 
the presence of Matuzumab, EGF could 
only contact domain III (or domain I), and 
its affinity for EGFR would be reduced—
exactly what is observed. Schmiedel et 
al. also show that Cetuximab and Matu-
zumab do not compete for binding to 
EGFR, as predicted from comparison of 
crystal structures of their complexes with 
EGFR, and suggest that combination 
therapy with Cetuximab (or IMC-11F8) 
and Matuzumab may result in added clini-
cal benefit.
It is clear that basic and clinical studies 
of the ErbB family of receptors have come 
a long way in the last few years. The results 
from each type of inquiry has informed the 
other, and together, they are leading to a 
deeper understanding of ErbB function 
and how to treat ErbB-involved diseases. 
It is also clear that much remains to be 
learned, and exciting times are ahead.
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In vertebrate cells, the small ubiquitin-like modifier SUMO plays a poorly defined role in targeting DNA topoi-
somerase II (TopoII) to centromeres (CENs) during mitosis, presumably to facilitate the untangling of sister 
chromatids as cells transition into anaphase. A new study by Dawlaty in the April 4 issue of Cell identifies 
the nucleoporin RanBP2 as a novel tumor suppressor that acts as a SUMO ligase for TopoII. Analysis of this 
interaction reveals TopoII recruitment to CENs is likely to play an important role in preventing chromosome 
segregation errors that lead to cancer.RanBP2 is a remarkably large (350 kD!) 
protein that contains, as its only enzy-
matic function, an unusual SUMO E3 
ligase domain (Pichler et al., 2002). In 
the final step of SUMO modification, the 
E2 conjugating enzyme Ubc9 transfers 
activated SUMO moieties to lysines on 
substrate proteins. This reaction typi-
cally requires, or is greatly stimulated by, 
SUMO E3 ligases. The best understood 
SUMO E3s are the PIAS family of pro-
teins, which contain a RING finger motif 
and promote sumolyation by recruiting substrates to the E2 enzyme (Jackson, 
2001). The RanBP2 E3 domain, in con-
trast, fits tidily within a ~300 amino acid 
segment that is structurally unrelated to 
PIAS proteins. Rather than binding sub-
strates, this E3 acts more like a cofac-
tor for Ubc9, possibly serving to directly 
stimulate E2 catalysis (Reverter and 
Lima, 2005).
The cell biology of RanBP2 has also 
provided surprises. In addition to bind-
ing Ubc9, the RanBP2 E3 domain inter-
acts specifically with SUMO-modified Cancer forms of RanGAP1. During interphase, 
this complex localizes to the cytoplas-
mic face of the nuclear pore. But once 
mitosis is underway, the entire RanBP2-
SUMO~RanGAP1-Ubc9 complex part-
ners with the nuclear export receptor 
Crm1 and moonlights as a component 
of the kinetochore (K; Arnaoutov et 
al., 2005). This is arguably even more 
important than RanBP2’s day job, as 
RanBP2 depletion produces severe 
mitotic defects, including perturbations 
to K-microtubule (MT) attachment, mis-Cell 13, April 2008 ©2008 Elsevier Inc. 293
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assembly checkpoint (SAC) 
proteins, and formation of 
multipolar spindles (Joseph 
et al., 2004). How RanBP2 
promotes K assembly/activ-
ity and whether SUMO ligase 
activity is involved in these 
functions is unknown.
Against this backdrop, the 
current study (Dawlaty et 
al., 2008) sets out to exam-
ine RanBP2 function in an 
intact organism. To circum-
vent lethality associated with 
a complete loss of RanBP2, 
they used a clever RNA 
splicing strategy to create 
a hypomorphic allele (ran-
BP2H) that lowers RanBP2 
protein levels to ~31%. ran-
BP2H was combined with 
knockout or wild-type alleles 
to create an allelic series of 
RanBP2-deficient animals. 
As expected, ranBP2−/− mice 
died during embryogenesis, 
but ranBP2−/H and ranBP2H/H 
individuals developed nor-
mally and survived into adult-
hood. Over a 2 year period, 
these mutants succumbed to 
a range of cancers, primarily 
lung carcinomas, and were also suscep-
tible to chemically-induced tumorigen-
esis. Thus, RanBP2 plays an unantici-
pated role in tumor suppression.
Insight into how RanBP2 might act as 
a tumor suppressor came with the find-
ing that RanBP2-deficient cancer cells 
displayed severe chromosome insta-
bility, pointing toward aneuploidy as a 
factor controlling tumor initiation or pro-
gression. Consistent with this, spleno-
cytes and embryonic fibroblasts (MEFs) 
derived from ranBP−/H and ranBPH/H 
mice exhibited chromosome segrega-
tion errors, typically gain/loss of single 
chromosomes, although more dramatic 
ploidy alterations were also observed. 
Given the role of RanBP2 at the K, one 
might suspect these missegregation 
events would correspond with defective 
chromosome-spindle attachment. Sur-
prisingly, this did not appear to be the 
case, and Dawlaty et al. went to some 
lengths to show that spindle structure, 
K-MT interactions, and localization of 
K and SAC proteins appeared normal 
in ranBP−/H and ranBPH/H cells. Instead, 
the most prevalent mitotic defect they 
observed was anaphase chromosome 
bridging, a hallmark of interference with 
TopoII function.
TopoII (TopoIIα in vertebrates) is 
essential for chromosome segregation 
because it performs the DNA surgery 
necessary to decatenate replicated 
chromosomes. In vertebrates, there is 
a specifically regulated component of 
decatenation in which TopoII preferen-
tially accumulates at CEN regions as 
cells approach the metaphase to ana-
phase transition (Figure 1). Previous 
studies have implicated sumolyation in 
TopoII CEN localization. In Xenopus, 
PIASy, a PIAS E3 family member that 
binds mitotic chromosomes, is required 
for TopoII SUMO conjugation (Azuma 
et al., 2005). PIASy depletion prevents 
SUMO conjugates from accumulat-
ing at CENs and interferes with sister 
chromatid disjunction. In a seemingly 
analogous fashion, RNAi 
knockdown of PIASy in 
human cells perturbs TopoII 
CEN targeting and delays 
anaphase entry (Diaz-Marti-
nez et al., 2006). Chromatid 
connections persist in PIASy 
knockdown cells even when 
cohesin complexes dissoci-
ate from DNA, arguing the 
separation block is due to 
reduced TopoII activity.
Based on these observa-
tions, Dawlaty et al. tested 
whether RanBP2 E3 activ-
ity was involved in TopoII 
sumolyation. To summarize 
their data, they showed 
ranBP2H/H and ranBP2H/− 
MEFs failed to target TopoII 
to CENs. Significantly, the 
RanBP2 E3 domain was suf-
ficient to rescue RanBP2-de-
ficient phenotypes, includ-
ing TopoII CEN localization 
and chromosome-bridging 
defects. The E3 domain also 
stimulated TopoII sumolyat-
ion in vitro, and ranBP2−/H 
cells (but not PIASy−/− cells) 
lacked detectable TopoII 
SUMO conjugates. Finally, 
an overproduced N-termi-
nal SUMO-TopoII fusion localized to 
CENs and prevented chromosome 
bridging in RanBP−/H mutants, provid-
ing evidence that TopoII is likely to be 
the SUMO substrate responsible for 
these phenotypes. There is a potential 
caveat, as this construct was not com-
pared to equivalently overproduced 
unfused TopoII. Nonetheless, the data 
suggest that, at least in MEFs, RanBP2 
rather than PIASy is the E3 ligase used 
for TopoII sumolyation. Different cells 
may employ different E3s, and a next 
step should be to clarify the roles of 
PIASy and RanBP2 in human cells. The 
more significant conclusion, however, 
is that RanBP2’s role in maintaining 
chromosome stability and potentially 
also tumor suppression appears to be 
directed through TopoII sumolyation. It 
will be important to determine whether 
these aspects of RanBP2 and TopoII 
function are associated with spontane-
ous or chemotherapy-induced tumors 
in humans.
figure 1. TopoII sumolyation and function within CEN chromatin
TopoII sumolyation has been described in a number of organisms, occurring 
during mitosis and in response to some forms of DNA damage. In yeast, the 
SUMO acceptor lysines are located in the noncatalytic C terminus of the pro-
tein. Current information regarding SUMO E3 ligases catalyzing TopoII sumo-
lyation is shown; the role of E1 and E2 enzymes is not depicted. SUMO iso-
peptidases (Ulp2/Smt4 in yeast, presumably a member of the SENP family in 
vertebrates) deconjugate SUMO from Topo II. Although the underlying mech-
anism is unclear (?), sumolyation facilitates TopoII enrichment to CEN regions 
of vertebrate chromosomes, presumably to help resolve a final population of 
catenates so chromatids disjoin properly—the act of segregation may even 
impart a direction to the TopoII reaction that favors this final decatenation 
step. As proposed by Dewlaty et al., reduced TopoII sumolyation in RanBP2-
deficient cells leads to a failure to recruit TopoII to CENs, producing anaphase 
chromosome bridging and the formation of aneuploid cells. Nondisjuction, as 
observed in yeast top2 mutants, would be expected to be one mechanism 
contributing to aneuploidy, but the actual sequence(s) of events producing 
aneuploidy in RanBP2-deficient cells remains to be described (?).294 Cancer Cell 13, April 2008 ©2008 Elsevier Inc.
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comment. First, how does SUMO liga-
tion promote TopoII enrichment at CENs? 
A straightforward model is that SUMO-
conjugated forms of TopoII bind receptors 
within CEN chromatin. However, as is the 
case with most SUMO substrates, only a 
small fraction of TopoII is actually sumo-
lyated at any one time. As suggested by 
Dawlaty et al., SUMO modification may 
only be required for an initial step in recruit-
ment, allowing TopoII to remain associated 
with CENs following SUMO deconjuga-
tion (Figure 1). Alternatively, sumolyation 
may promote a different aspect of TopoII 
dynamics, such as enzyme turnover on 
chromatin, which then indirectly facilitates 
CEN targeting through a different pathway. 
Further analysis of the genetic require-
ments for TopoII CEN localization, as well 
as determining if there are factors that bind 
sumolyated TopoII, should help clarify the 
recruitment mechanism.
Second, previous studies have shown 
that TopoII inhibition (or PIASy knockdown) 
during mitosis can activate a preana-
phase checkpoint that exhibits consider-
able overlap with the SAC (Diaz-Martinez pVHL and HIF
von Hippel-Lindau (VHL) disease is a 
hereditary cancer syndrome character-
ized by a spectrum of benign and malig-
nant tumors including retinal heman-
giomas, cerebellar hemangioblastomas, 
pheochromocytomas, and renal cell 
carcinomas (Kaelin, 2002). Patients with 
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Loss of the VHL tumor suppressor 
transcription factors. HIF overexpre
why is the spectrum of tumors asso
paper in the March issue of Natur
suggesting that VHL loss can also tet al., 2006). The lesion inducing this 
response is unclear, but one idea is that 
a catenate-counting mechanism delays 
anaphase until chromatid entanglements 
fall below a threshold level. In the current 
study, it is notable that failure to com-
pletely decatenate CENs did not appear 
to activate such a checkpoint response. 
Similarly, yeast top2 mutants that exhibit 
a lethal decatenation defect proceed into 
anaphase with normal cell-cycle kinetics. 
In yeast, TopoII SUMO modification is not 
required for efficient chromatid disjunc-
tion (Bachant et al., 2002) and is largely, 
but not completely, dispensable for chro-
mosome segregation (Takahashi et al., 
2006). One phenotype observed in yeast 
SUMO-resistant top2 mutants, however, 
is a failure to maintain CEN compaction 
under tension as chromatids biorient on 
the spindle (Bachant et al., 2002). Could 
TopoII be mediating additional functions 
within CEN chromatin, and might these 
activities, rather than decatenation, be 
influencing the SAC? The newfound con-
nections between TopoII, SUMO, CENs, 
and cancer suggest the answers may 
prove interesting.Cancer
VHL disease inherit a faulty allele of the 
ubiquitously expressed VHL tumor sup-
pressor gene, and emergence of pathol-
ogy in these patients follows the inacti-
vation of the remaining wild-type allele.
The gene product of VHL, pVHL, acts 
as the substrate recognition component 
of an E3 ubiquitin ligase complex (Kae-
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